Mesut Gumussoy

Mesut Gumussoy

Auto-generated profile, based on publicly available information

Mesut Gumussoy

Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkiye

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2023 in Hepatology
Verified
Journal Article
Closed access
BKBeom Kyung Kim
Beom Kyung Kim
JBJaclyn Bergstrom
Jaclyn Bergstrom
RLRohan Loomba
Rohan Loomba
NTNobuharu Tamaki
Nobuharu Tamaki
NINamiki Izumi
Namiki Izumi
VAVeeral Ajmera
Veeral Ajmera
Background and Aims: Magnetic resonance elastography (MRE) is an accurate, continuous biomarker of liver fibrosis; however, the optimal combination with clinical factors to predict the risk of incident hepatic decompensation is unknown. Therefore, we aimed to develop and validate an MRE-based prediction model for hepatic decompensation for patients with NAFLD. Approach and Results: This international multicenter cohort study included participants with NAFLD undergoing MRE from 6 hospitals. A total of 1254 participants were randomly assigned as training (n = 627) and validation (n = 627) cohorts. The primary end point was hepatic decompensation, defined as the first occurrence of variceal hemorrhage, ascites, or HE. Covariates associated with hepatic decompensation on Cox-regression were combined with MRE to construct a risk prediction model in the training cohort and then tested in the validation cohort. The median (IQR) age and MRE values were 61 (18) years and 3.5 (2.5) kPa in the training cohort and 60 (20) years and 3.4 (2.5) kPa in the validation cohort, respectively. The MRE-based multivariable model that included age, MRE, albumin, aspartate aminotransferase, and platelets had excellent discrimination for the 3- and 5-year risk of hepatic decompensation (c-statistic 0.912 and 0.891, respectively) in the training cohort. The diagnostic accuracy remained consistent in the validation cohort with a c-statistic of 0.871 and 0.876 for hepatic decompensation at 3 and 5 years, respectively, and was superior to Fibrosis-4 in both cohorts (p < 0.05). Conclusions: An MRE-based prediction model allows for accurate prediction of hepatic decompensation and assists in the risk stratification of patients with NAFLD.

23 September 2022 in Hepatology Forum
Verified
Journal Article
Open access
PDF file
FGFatih Güzelbulut
Fatih Güzelbulut
UKUmit Karaogullarindan
Umit Karaogullarindan
HAHikmet Akkiz
Hikmet Akkiz
EAEngin Altintas
Engin Altintas
CDCoskun Ozer Demirtas
Coskun Ozer Demirtas
RIRamazan Idilman
Ramazan Idilman
Background and Aim: The aim of the present study was to examine the etiology of hepatocellular carcinoma (HCC) by underlying cause and determine the characteristics and clinical features of patients with HCC. Materials and Methods: The study comprised 1802 HCC patients diagnosed and followed up by Liver Diseases Outpatient Clinics in 14 tertiary centers in Turkey between 2001 and 2020. Results: The mean age was 62.3±10.7 years, and 78% of them were males. Of the patients, 82% had cirrhosis. Hepatitis B virus (HBV) infection was the most common etiology (54%), followed by hepatitis C virus (HCV) infection (19%) and nonalcoholic fatty liver disease (NAFLD) (10%). Of the patients, 56% had a single lesion. Macrovascular invasion and extrahepatic spread were present in 15% and 12% of the patients, respectively. The median serum alpha-fetoprotein level was 25.4 ng/mL. In total, 39% of the patients fulfilled the Milan Criteria. When we compared the characteristics of patients diagnosed before and after January 2016, the proportion of NAFLD-related HCC cases increased after 2016, from 6.6% to 13.4%. Conclusion: Chronic HBV and HCV infections remain the main causes of HCC in Turkey. The importance of NAFLD as a cause of HCC is increasing.

23 February 2023 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
MKMuhammed Fatih Karakaya
Muhammed Fatih Karakaya
EEErdem Er
Erdem Er
EKElvan Onur Kirimker
Elvan Onur Kirimker
MGMesut Gümüşsoy
Mesut Gümüşsoy
EBEmin Bodakçi
Emin Bodakçi
RIRamazan Idilman
Ramazan Idilman
Background: The aims of this study were to investigate biliary complications in liver transplant recipients with choledochocholedocho stomy anastomosis, to identify the risk factors for the development of such complications, and to evaluate the success of endoscopic approaches in liver transplant recipients. Methods: Between January 2013 and May 2021, a total of 238 patients with liver diseases underwent liver transplantation: 174 recipients undergoing choledochocholedochostomy anastomosis were included in the analysis. Results: Their median age was 54.0 years. The median posttransplant follow-up period was 29 months. Hepatitis B virus infection (33%) was the most common indication for liver transplantation. Most patients (87%) received living donor liver transplantation. The overall prevalence of posttransplant biliary complications was 31%. Anastomotic biliary strictures were the most common biliary complications (72%), followed by biliary leakage (13%). The median time between endoscopic retrograde cholangiography and liver transplantation was 4 months, with a mean of 3 ± 1.6 sessions. Endoscopic retrograde cholangiography-guided drainage and balloon dilation with or without stent placement was the most common treatment modalities for recipients with biliary strictures. The overall success rate of endoscopic treatment modalities was 83.3%, with 65% of the recipients exhibiting complete biochemical and endoscopic responses. The response did not differ significantly between living donor liver transplantation and cadaveric donor liver transplant recipients (P > .05). Three recipients required revision surgery for biliary complication repair. Six patients died due to biliary sepsis. Conclusion: Biliary stricture and leakages were the most common biliary complications after liver transplantation. Endoscopic treatment was successful in most recipients. Cite this article as: Karakaya MF, Er E, Kırımker O, et al. Management of biliary complications in liver transplant recipients with duct-to-duct anastomosis: A single-center experience. Turk J Gastroenterol. 2023;34(2):177-181.

1 January 2026 in Hepatology Forum
Verified
Journal Article
Open access
PDF file
EBEmin Bodakci
Emin Bodakci
SKSaba Kiremitci
Saba Kiremitci
ZEZeynep Melekoglu Ellik
Zeynep Melekoglu Ellik
OKOzge Koc
Ozge Koc
MGMesut Gumussoy
Mesut Gumussoy
RIRamazan Idılman
Ramazan Idılman
Background and Aim: The present study aimed to determine the effect of hepatic steatosis, as detected by liver biopsy, on Hepatitis B surface antigen (HbsAg) seroclearance and disease progression in patients infected with hepatitis B virus (HBV). Materials and Methods: Patients with chronic HBV infection and chronic hepatitis B (CHB) from an existing cohort of HBV-infected patients were enrolled. Results: This study included 296 patients: 186 with chronic HBV in-fection and 110 with CHB. Patients with chronic HBV infection were older (p=0.006), and exhibited a higher prevalence of wild-type mutants (p

15 August 2024 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
MÖMübin Özercan
Mübin Özercan
ZEZeynep Melekoğlu Ellik
Zeynep Melekoğlu Ellik
APAyhan Parmaksız
Ayhan Parmaksız
MGMesut Gümüşsoy
Mesut Gümüşsoy
SDSerkan Duman
Serkan Duman
NÖNecati Örmeci
Necati Örmeci
Background/Aims: The presence of liver fibrosis is the most important indicator of progression to cirrhosis. Noninvasive measurement of liver stiffness is crucial for detecting fibrosis. Vibration-controlled transient elastography is one of the most useful methods for this purpose. We aimed to compare the liver stiffness and steatosis measurements with iLivTouch© and the FibroScan© elastography devices Materials and Methods: Two hundred thirty-seven consecutive adult patients with chronic hepatitis were included in the study. The liver stiffness and steatosis were measured with iLivTouch and FibroScan on the same day. Thirty-one patients had liver biopsies on the same day with elastography procedures. The diagnostic performances of iLivTouch and FibroScan were compared to aspartate aminotransferase to platelet ratio index (APRI), Fibrosis-4 (FIB-4), and nonalcoholic fatty liver disease fibrosis score (NFS). Results: The liver stiffness measurements obtained using iLivTouch and FibroScan had median value of 10.3 (ranging from 2.9 to 46.3) and 7.2 (ranging from 2.5 to 75), respectively. The mean steatosis measurements using ultrasound attenuation parameter with iLivTouch were 245.51 ± 45.79, while the mean controlled attenuation parameter measurements using FibroScan were 259.37 ± 75.0. In subgroup analysis, the AUC of iLivTouch on detecting signiicant fibrosis [0.83, (P = .002)] was minimally higher than other noninvasive methods [0.82 for NFS (P = .003), 0.80 for FibroScan (P = .006), 0.68 for FIB-4 (P = .089), and 0.53 for APRI (P = .76)]. Conclusion: The stiffness and steatosis measurements with iLivTouch and FibroScan were not similar. The accuracy of iLivTouch in detecting significant and advanced fibrosis was minimally higher. Large clinical trials are necessary to support these findings. Cite this article as: Özercan M, Melekoğlu Ellik Z, Parmaksız A, Gümüşsoy M, Duman S, Örmeci N. Liver stiffness and steatosis measurements with iLivTouch and FibroScan: A comparative study. Turk J Gastroenterol. 2024;35(8):634-642.

1 January 2018 in Van Medical Journal
Verified
Journal Article
Open access
MGMesut Gümüşsoy
Mesut Gümüşsoy
RBRemzi Bahşi
Remzi Bahşi
DSDeniz Mut Sürmeli
Deniz Mut Sürmeli
TTTuğba Turgut
Tuğba Turgut
HÖHande Selvi SELVİ Öztorun
Hande Selvi SELVİ Öztorun
SASevgi Aras
Sevgi Aras